Skip to Content

PRIMECAP Odyssey Growth POGRX

Medalist Rating as of | See PRIMECAP Investment Hub
  • NAV / 1-Day Return 37.15  /  −0.93 %
  • Total Assets 6.3 Bil
  • Adj. Expense Ratio
    0.660%
  • Expense Ratio 0.660%
  • Distribution Fee Level Below Average
  • Share Class Type No Load
  • Category Large Growth
  • Investment Style Large Growth
  • Min. Initial Investment 2,000
  • Status Open
  • TTM Yield 0.44%
  • Turnover 7%

USD | NAV as of Apr 16, 2024 | 1-Day Return as of Apr 16, 2024, 12:08 AM GMT+0

Morningstar’s Analysis POGRX

Will POGRX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Still strong after a rough half-decade.

Strategist Robby Greengold

Robby Greengold

Strategist

Summary

With its outstanding investment team and unique multimanager approach, Primecap Odyssey Growth is exemplary.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings POGRX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 30.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

7.64 523.4 Mil
Healthcare

Splunk Inc

3.38 231.2 Mil
Technology

Biogen Inc

2.97 203.5 Mil
Healthcare

AECOM

2.79 191.4 Mil
Industrials

Biomarin Pharmaceutical Inc

2.37 162.2 Mil
Healthcare

Micron Technology Inc

2.33 159.9 Mil
Technology

Raymond James Financial Inc

2.32 158.6 Mil
Financial Services

Microsoft Corp

2.28 156.4 Mil
Technology

Amgen Inc

2.27 155.5 Mil
Healthcare

Flex Ltd

2.10 143.7 Mil
Technology